U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra

Altair Engineering

23/02/2024 07:28

Feb 23 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Biomarin Pharmaceutical, Intuit and
Penumbra, on Friday. 
    
    HIGHLIGHTS
    
                 * Biomarin Pharmaceutical Inc  BMRN.O : Piper Sandler cuts target price to $107 from $115
 
                 * Intuit Inc  INTU.O : Susquehanna raises target price to $775 from $700
 
                 * Penumbra Inc  PEN.N : JP Morgan cuts to neutral from overweight
 
        
Following is a summary of research actions on U.S. companies reported by Reuters on Friday.
Stock entries are in alphabetical order. 

                 * Agios Pharmaceuticals Inc  AGIO.O : JP Morgan cuts target price to $30 from $31
 
                 * Alarm.Com Holdings Inc  ALRM.O : JP Morgan raises target price to $70 from $62
 
                 * Altair Engineering Inc  ALTR.O : Oppenheimer raises target price to $100 from $95
 
                 * Arcutis Biotherapeutics Inc  ARQT.O : Mizuho raises target price to $16 from $8
 
                 * Ardelyx Inc  ARDX.O : Piper Sandler raises target price to $15 from $12
 
                 * Biomarin Pharmaceutical Inc  BMRN.O : Piper Sandler cuts target price to $107 from
 $115
 
                 * Block Inc  SQ.N : Piper Sandler raises target price to $88 from $86
 
                 * Bridge Investment Group Holdings Inc  BRDG.N : JP Morgan cuts PT to $11.5 from $13.5
 
                 * Carter'S Inc  CRI.N : Wedbush raises target price to $78 from $67
 
                 * Chuy's Holdings Inc  CHUY.O : Piper Sandler cuts target price to $35 from $39
 
                 * Collegium Pharmaceutical Inc  COLL.O : Piper Sandler raises PT to $39 from $37
 
                 * CS Disco Inc  LAW.N : Piper Sandler raises target price to $7.5 from $6.5
 
                 * Envestnet Inc  ENV.N : JP Morgan raises target price to $45 from $44
 
                 * FIS  FIS.N : JP Morgan raises target price to $71 from $68
 
                 * Floor & Decor Holdings Inc  FND.N : Piper Sandler raises target price to $105 from $98
 
                 * Guardant Health Inc  GH.O : JP Morgan cuts target price to $45 from $60
 
                 * Guardant Health Inc  GH.O : Leerink Partners cuts target price to $50 from $55
 
                 * Ideaya Biosciences Inc  IDYA.O : JP Morgan raises target price to $57 from $51
 
                 * Insulet Corp  PODD.O : JP Morgan raises target price to $225 from $190
 
                 * Intuit Inc  INTU.O : JP Morgan raises target price to $585 from $560
 
                 * Intuit Inc  INTU.O : Susquehanna raises target price to $775 from $700
 
                 * IRhythm Technologies Inc  IRTC.O : JP Morgan cuts target price to $133 from $142
 
                 * Kymera Therapeutics Inc  KYMR.O : JP Morgan raises target price to $47 from $34
 
                 * Kymera Therapeutics Inc  KYMR.O : Leerink Partners raises target price to $33 from $28
 
                 * Neurocrine Biosciences Inc  NBIX.O : JP Morgan cuts target price to $148 from $154
 
                 * Penumbra Inc  PEN.N : JP Morgan cuts target price to $250 from $284
 
                 * Penumbra Inc  PEN.N : JP Morgan cuts to neutral from overweight
 
                 * Planet Fitness Inc  PLNT.N : Stifel cuts target price to $80 from $85
 
                 * TPI Composites Inc  TPIC.O : Piper Sandler cuts target price to $3 from $4
 
                 * Vir Biotechnology Inc  VIR.O : JP Morgan raises target price to $10 from $9
 
                 * Wayfair Inc  W.N : Piper Sandler cuts target price to $88 from $93
 
 
 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))